Progression independent of relapse activity (PIRA) in relapsing-remitting multiple sclerosis patients on first-line immunomodulatory treatment with fingolimod vs. platform injectables
MULTIPLE SCLEROSIS JOURNAL(2019)
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined